STOCK TITAN
  1. Home
  2. News
  3. TLSA

Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing alternative routes of immunotherapy with a focus on innovative drugs for neurodegenerative diseases, including treatment with intranasal foralumab for Secondary Progressive Multiple Sclerosis, today announced its Chief Executive Officer and Chief Scientific Officer, Kunwar Shailubhai, Ph.D., will participate in a fireside chat at the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference on Wednesday, April 27, 2022 at 2:30 p.m. ET (U.S. and Canada) to provide Company updates.

Date:Wednesday, April 27, 2022
Time:2:30 p.m. Eastern Time (U.S. and Canada)
Webcast:Click this link to access: https://www.webcaster4.com/Webcast/Page/2875/45361
  

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further information please contact:
Tiziana Life Sciences:
Hana Malik, Business Development and Investor Relations Manager 
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

United States:
Investors:
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com


Stock TLSA logo
Tiziana Life Sciences Ltd

NASDAQ:TLSA

TLSA Rankings

#4503 Ranked by Market Cap
#2682 Ranked by Stock Gains
N/A Ranked by Dividends

TLSA Latest News

May 13, 2024
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
Apr 25, 2024
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
Apr 23, 2024
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
Apr 22, 2024
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
Apr 19, 2024
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

TLSA Stock Data

75.19M
61.41M
38.04%
0.78%
0.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
London

About TLSA

tiziana life sciences plc is a uk biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. the company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (cdk) involved in cell division as well as a number of other protein kinases. milciclib is currently in phase ii clinical trials for thymic carcinoma in patients previously treated with chemotherapy. the company is also in clinical development of foralumab. foralumab is the only fully human engineered anti-human cd3 antibody in clinical development. this phase ii compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (t1d), inflammatory bowel disease (ibd), psoriasis and rheumatoid arthritis, where modulation of a t-cell response is desirable. tiziana life sciences’ research